{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:51:54Z","timestamp":1790787114565,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:24:25Z","timestamp":1710476665000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients"],"prefix":"10.1016","volume":"237","author":[{"given":"H.","family":"L\u00e9vesque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Houivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bonnotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Le Cam-Duchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Liozon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hervier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ebbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ferreira-Maldent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Babuty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Barbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Audia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Benichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Graveleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.thromres.2024.03.012_bb0005","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1160\/TH13-05-0363","article-title":"Acquired haemophilia A: a 2013 update","volume":"110","author":"Franchini","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.012_bb0010","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.012_bb0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.012_bb0035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.thromres.2024.03.012_bb0040","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2024.03.012_bb0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.012_bb0050","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.012_bb0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.thromres.2024.03.012_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2024.03.012_bb0065","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"48","key":"10.1016\/j.thromres.2024.03.012_bb0070","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005232","article-title":"Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: a retrospective single-center study","volume":"95","author":"Vautier","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.thromres.2024.03.012_bb0075","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2006.11.004","article-title":"Rituximab in the treatment of adult acquired hemophilia A: a systematic review","volume":"63","author":"Franchini","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.thromres.2024.03.012_bb0085","article-title":"Rituximab for eradicating inhibitors in people with acquired haemophilia A","volume":"8","author":"Remminghton","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.012_bb0090","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/hae.12973","article-title":"Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience","volume":"22","author":"Rossi","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2024.03.012_bb0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.revmed.2021.07.003","article-title":"Characterizing hospital pathways for the care of acquired hemophilia in France using comprehensive national health data","volume":"43","author":"Guillet","year":"2022","journal-title":"Rev. Med. Interne"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.thromres.2024.03.012_bb0105","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2024.03.012_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2023.11.025","article-title":"Characteristics and outcomme of a territory-wide cohort study of patients with acquired hemiphilia A in Hong Kong","volume":"233","author":"Sin","year":"2024","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnoses acquired hemophilia A: a multicenter, open-label, randomized non inferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.012_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.012_bb0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.012_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.03.012_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.012_bb0140","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemopilia"},{"issue":"11","key":"10.1016\/j.thromres.2024.03.012_bb0150","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GHT-AHAZ-EMI): an open-label, single arm; multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.012_bb0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A low-dose rituximab regimen for first-line treatment of acquired haemophilia A","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"18","key":"10.1016\/j.thromres.2024.03.012_bb0160","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T01:19:39Z","timestamp":1714094379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"alternative-id":["S0049384824000835"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.012","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}